Sun N, Sun S G, Lu Z L, He J
Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2018 Jun 23;40(6):418-421. doi: 10.3760/cma.j.issn.0253-3766.2018.06.004.
To investigate the tumor-associated protein molecules carried by plasma exosomes of patients with lung squamous cell carcinoma before treatment and analyze their value as clinical markers. Exosomes from 2 patients with lung squamous cell carcinoma before treatment and 2 healthy controls were collected by ultracentrifugation. Proteomics was applied to analyze the protein expression profiles of exosomes. Candidate molecules were verified in another 30 exosomes samples from lung squamous cell carcinoma and healthy controls using enzyme-linked immunosorbent assay (ELISA). Electron microscopy and particle-counting assay showed that high-quality exosomes were collected. The number of exosomes distributed from 45 to 135 nm in 2 cases of lung cancer patients were 7.89×10(11)/ml and 9.71×10(11)/ml, respectively, significantly higher than 2.76×10(11)/ml and 1.41×10(11)/ml in healthy controls. Proteomic analysis showed that proteins of exosomes in lung squamous cell carcinoma patients were very different from those of healthy controls, and some proteins are related to important functions in tumor progression. 14-3-3ζ from exosomes was selected and further verified as a marker, and the area under the receiver operating characteristic curve (ROC) was 0.68. The sensitivity and specificity of 14-3-3 ζ from exosomes were 60.0% and 80.0%, respectively, suggested that it could be used as a diagnostic marker for lung squamous cell carcinoma. The exosome counts in plasma and the protein molecules from exosomes, such as 14-3-3ζ, are closely related to the tumorigenesis, which can be used to assist clinical diagnosis of lung squamous cell carcinoma patients.
研究肺鳞状细胞癌患者治疗前血浆外泌体携带的肿瘤相关蛋白分子,并分析其作为临床标志物的价值。通过超速离心收集2例治疗前肺鳞状细胞癌患者和2例健康对照者的外泌体。应用蛋白质组学分析外泌体的蛋白质表达谱。使用酶联免疫吸附测定(ELISA)在另外30例肺鳞状细胞癌和健康对照的外泌体样本中验证候选分子。电子显微镜和颗粒计数分析表明收集到了高质量的外泌体。2例肺癌患者中直径分布在45至135nm的外泌体数量分别为7.89×10(11)/ml和9.71×10(11)/ml,显著高于健康对照中的2.76×10(11)/ml和1.41×10(11)/ml。蛋白质组学分析表明,肺鳞状细胞癌患者外泌体中的蛋白质与健康对照者有很大不同,一些蛋白质与肿瘤进展中的重要功能相关。选择外泌体中的14-3-3ζ并进一步验证为标志物,其受试者工作特征曲线(ROC)下面积为0.68。外泌体中14-3-3ζ的敏感性和特异性分别为60.0%和80.0%,表明其可作为肺鳞状细胞癌的诊断标志物。血浆中外泌体计数以及外泌体中的蛋白质分子,如14-3-3ζ,与肿瘤发生密切相关,可用于辅助肺鳞状细胞癌患者的临床诊断。